Fig. 1.

NDR1 modulates apoptosis and drug sensitivity in breast cancer cells. a, b NDR1 or control vector was expressed in SUM149 cells for 24 h. Then, SUM149 cells were treated with or without Epirubicin (2.5 µM) for 48 h. Cells were harvested and subjected to Annexin V-FITC staining, flow cytometry analysis and western blot analysis. c, d NDR1 siRNA or control siRNA were transfected in SUM149 cells for 24 h. Then, SUM149 cells were treated with or without Epirubicin (0.5 µM) for 48 h. Cells were harvested and subjected to Annexin V-FITC staining, flow cytometry analysis and western blot analysis. e NDR1 or control vector were expressed in MCF-7 cells for 24 h. Then, MCF-7 cells were treated with or without Epirubicin (2.5 µM) for 48 h. Cells were harvested and subjected to Annexin V-FITC staining and flow cytometry analysis. f NDR1 siRNA or control siRNA were transfected in MCF-7 cells for 24 h. Then, MCF-7 cells were treated with or without Epirubicin (0.5 µM) for 48 h. Cells were harvested and subjected to Annexin V-FITC staining and flow cytometry analysis. g NDR1 or control vector were expressed in SUM149 cells for 24 h. Then, SUM149 cells were treated with or without Taxol (20 nM) for 48 h. Cells were harvested and subjected to Annexin V-FITC staining and flow cytometry analysis. h NDR1 siRNA or control siRNA were transfected in SUM149 cells for 24 h. Then, SUM149 cells were treated with or without Taxol (5 nM) for 48 h. Cells were harvested and subjected to Annexin V-FITC staining and flow cytometry analysis. The bar represents mean ± SD of three independent experiments (*: p < 0.05, **: p < 0.01, ***: p < 0.001)